LAVA Therapeutics NV
LVTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$45.77M
Close$
$-2.51
244.5% downside
Current Fair Value
244.5% downsideOvervalued by 244.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $45.77 Million |
|---|---|
| Enterprise Value | $31.11 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.94 |
| Beta | 0.5 |
| Outstanding Shares | 26,899,122 |
Return
| Return on Equity | -183.50% |
|---|---|
| Return on Assets | -44.83% |
| Return on Invested Capital | -23.81% |
Valuation & Multiples
| P/E Ratio | -2.01 |
|---|---|
| PEG | 4.84 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.23 |
| Enterprise Value to EBIT | -2.74 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.13 |
| Debt to Equity | 2.76 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 6, 2025
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3951▲ 39.51% |
|---|---|
| Total Calls | 130,600▲ 633.71% |
| Total Puts | 51,600▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 38.39%▲ 8.45% |
|---|---|
| Total Invested | $16.11M▲ 51.55% |
| Investors Holding | 25▲ 5.00% |
ESG Score
No data
About LAVA Therapeutics NV
LAVA Therapeutics N.V. is a biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary platform. The...